EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunostimulatory gene therapy with chemotherapy remodels pancreatic tumors and induces immune signatures associated with prolonged survival

Jessica Wenthe, Hanna Grauers Wiktorin, Amanda Hahn, Sedigheh Naseri, Ahmed Calandigary, Luke White, Linda C Sandin, Clara Bernedal Nordström, Stephan Mielke, Tanja Lövgren, Gustav J Ullenhag, Angelica Loskog

Journal for ImmunoTherapy of Cancer · 2026-10 · 14 (10) · e016908

DOI: 10.1136/jitc-2026-016908 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 28.10.2026. Verfasst von Jessica Wenthe und 11 weiteren Autor:innen. Beteiligte Einrichtung: Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Cancerfonden, Barncancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune desert/excluded tumors remain a major immunotherapeutic challenge. Herein, we aim to describe mechanistic insights of LOAd703, a novel tumor microenvironment gene engineering therapy targeting CD40 and 4–1BB, in patients with advanced solid cancer commonly associated with unresponsiveness to immunotherapy.

Methods

The study evaluated blood and biopsy samples from pancreatic (n=29), colorectal (n=5), biliary (n=3), and ovarian cancer (n=4), treated with LOAd703 in combination with chemotherapy in a Swedish phase I/II clinical trial (NCT032259899).

Results

Transcriptomic profiling of tumors before and after treatment initiation revealed induction of signatures known to predict immunotherapy responses and an enrichment for adaptive immune response pathways encompassing antigen-presentation and T-cell activation. In pancreatic cancer subanalysis, adaptive immune responses together with increased CD40 expression were associated with longer survival and CD40 appeared as a central node among upregulated immune biomarkers consistent with the mechanism of action of LOAd703. Treatment benefit was further associated with reduced expression of immunosuppressive and tumor-promoting factors both in tumors and peripheral blood. Systemically, treatment generated a Th1 profile in plasma, accompanied by an increase in effector/effector memory T cells and a reduction of regulatory T cells.

Conclusions

These findings support that intratumoral LOAd703 in combination with chemotherapy drives local and systemic immune remodeling in commonly immunotherapy-unresponsive tumors. Further, the treatment reprograms the tumor microenvironment to reduce tumor-promoting factors and immunosuppression.One sentence summary Targeting CD40 and 4–1BB with gene therapy in combination with chemotherapy induces immune responses associated with longer survival in pancreatic cancer.

Schlagwörter

Stichwörter der Autor:innen

Gene therapyImmunotherapyOncolytic virusTumor microenvironment - TME

Autor:innen und Institutionen

  • Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.
  • Lokon Pharma AB, Uppsala, Sweden.
  • Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska Institutet, Stockholm, Sweden.
  • Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden angelica.loskog@igp.uu.se.

Förderung

  • Vetenskapsrådet
  • Cancerfonden
  • Barncancerfonden
  • Lokon Pharma AB

Zitieren

APA

Wenthe, J., Grauers Wiktorin, H., Hahn, A., Naseri, S., Calandigary, A., White, L., Sandin, L. C., Bernedal Nordström, C., Mielke, S., Lövgren, T., Ullenhag, G. J., & Loskog, A. (2026). Immunostimulatory gene therapy with chemotherapy remodels pancreatic tumors and induces immune signatures associated with prolonged survival. Journal for ImmunoTherapy of Cancer, 14(10), e016908. https://doi.org/10.1136/jitc-2026-016908

Vancouver

Wenthe J, Grauers Wiktorin H, Hahn A, Naseri S, Calandigary A, White L, et al. Immunostimulatory gene therapy with chemotherapy remodels pancreatic tumors and induces immune signatures associated with prolonged survival. Journal for ImmunoTherapy of Cancer. 2026;14(10):e016908. doi:10.1136/jitc-2026-016908

BibTeX
@article{Wenthe2026,
  author = {Wenthe, Jessica and Grauers Wiktorin, Hanna and Hahn, Amanda and Naseri, Sedigheh and Calandigary, Ahmed and White, Luke and Sandin, Linda C and Bernedal Nordström, Clara and Mielke, Stephan and Lövgren, Tanja and Ullenhag, Gustav J and Loskog, Angelica},
  title = {Immunostimulatory gene therapy with chemotherapy remodels pancreatic tumors and induces immune signatures associated with prolonged survival},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {10},
  pages = {e016908},
  doi = {10.1136/jitc-2026-016908}
}
Kostenlos starten →